Some examples and use cases from the internet:

Some examples and use cases from the internet:

• The LLNA studies the induction phase of skin sensitisation and provides quantitative data suitable for dose
• It studies the induction phase of skin sensitisation and provides quantitative data suitable for dose response assessment.
• Most of the withdrawals appear to be due to premature applications, with applicants unable to provide adequate additional information, data and responses even within a longer clock stop.
• Available data suggest that clinical response is usually achieved within 12 weeks of treatment.
• Optaflu has not been studied in the paediatric population and therefore, data on immune response are not available for this age group.
• Response data are shown in Table 3.
• In the case of low decay rates, the response data tends to be free from some of the problems indicated above.
• response assessment.

• tabulation of irritant/corrosive response data for each individual animal at each observation time point (e.g. 1, 24, 48 and 72 hours);
• Periodically the RU will compare the path request and the response data for producing reports as follows:
• Competent authorities shall evaluate dose response data generated in trials (which must include an untreated control) involving dose rates lower than the recommended rate, in order to assess if the recommended dose is the minimum necessary to achieve the desired effect.
• Member States shall evaluate dose response data generated in trials (which must include an untreated control) involving dose rates lower than the recommended rate, in order to assess if the recommended dose is the minimum necessary to achieve the desired effect.
• Immune response data are satisfactory for PROCOMVAX but are currently unavailable for DTaP.
• tabulation of response data and dose level for each animal (i.e. animals showing signs of toxicity including mortality, nature, severity and duration of effects),
• In the case of low decay rates, the response data tends to be free from some of the problems indicated above.
• Maternal toxic response data by dose, including but not limited to: